Osteoporosis in severe congenital neutropenia treated with granulocyte colony‐stimulating factor

1995/04/01 by Nick Bishop, N. J. Bishop, D. M. Williams +7 · 3 citations
Biochemistry, Genetics and Molecular Biology · Immunology and Microbiology · Medicine · #Blood disorders and treatments #Immunodeficiency and Autoimmune Disorders #Hematological disorders and diagnostics

paper · doi:10.1111/j.1365-2141.1995.tb08441.x

Abstract

Recombinant human granulocyte colony-stimulating factor (G-CSF) has substantially improved life expectancy for children with severe congenital neutropenia (SCN). Severe osteoporosis, reported in this population, may relate to the disease process, or be a therapeutic side-effect. This report details bone loss, quantitated absorptiometrically and histomorphometrically, in a child with SCN and vertebral collapse, and the positive response to anabolic steroid and bisphosphonate therapy.

Citations

• Long‐term safety of treatment with recombinant human granulocyte colony‐stimulating factor (r‐metHuG‐CSF) in patients with severe congenital neutropenias

Cited by

• ELANE mutations in cyclic and severe congenital neutropenia: genetics and pathophysiology. [europepmc]
• The effects of short-term use of granulocyte colony-stimulating factor on bone metabolism in child cancer patients. [europepmc]
• G‑CSF delays tooth extraction socket bone healing via the inhibition of bone turnover in mice. [europepmc]

Related

• Long‐term safety of treatment with recombinant human granulocyte colony‐stimulating factor (r‐metHuG‐CSF) in patients with severe congenital neutropenias
• Inborn errors of metabolism and osteopetrosis
• Osteogenesis imperfecta: shifting paradigms in pathophysiology and care in children
• The skeletal manifestations of the congenital disorders of glycosylation
• Effects of Child- and Adolescent-Onset Endogenous Cushing Syndrome on Bone Mass, Body Composition, and Growth: A 7-Year Prospective Study Into Young Adulthood